k8凯发(中国)天生赢家·一触即发

EIK1003 is a novel and potent PARP1 inhibitor that shows biochemical and cellular selectivity when compared to PARP2 which is a related enzyme that is thought to contribute disproportionately to the adverse effect profiles of currently marketed PARP 1/2 inhibitors. The selectivity of EIK1003 for PARP1 supports clinical study of this agent as monotherapy and potentially in combination with other treatment regimens.

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/IMP4297), WEE1 inhibitor (IMP7068), ATR inhibitor (IMP9064)，and PARP1 selective inhibitor (IMP1734, in collaboration with Eikon Therapeutics), as well as other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/IMP4297), has successfully completed Phase III pivotal trial in ovarian cancer first-line maintenance (FLAMES study) setting with best-in-class efficacy and safety profile. Based on the results of the FLAMES study, the Senaparib New Drug Application (NDA) has been accepted for review by the National Medical Products Administration (NMPA) of China. WEE1 inhibitor IMP7068 and ATR inhibitor IMP9064 is undergoing global Phase I clinical study. PARP1 selective inhibitor IMP1734 (EIK1003) has obtained IND clearance from U.S. FDA and National Medical Products Administration of China.